Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
Early Phase 1 N=50 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
N/A N=36 Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
Endometrial Carcinoma
Primary: Expression of Cell Cycle-related Proteins — 46.1; 0.8; 0.7 score on a scale — p=0.033
Phase 2 N=54 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
N/A N=10 Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?
Endometrial Cancer · Endometrial Neoplasms · Endometrial Hyperplasia
Primary: Number of Participants Whose Sample Was Successfully Analysed by Histological Diagnosis — 9 Participants
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=53 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants
Phase 2 N=35 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Endometrial Carcinoma
Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
Phase 2 N=11 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 3 N=336 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis
Menopause · Postmenopausal Vaginal Atrophy
Primary: Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies — 0; 0; 0; 0 percentage of participants
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Phase 2 N=35 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
Phase 2 N=28 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants